FDA approves icotrokinra, first oral peptide for adults and teens with plaque psoriasis

Summary: The FDA just approved a new pill called Icotyde (icotrokinra) to treat moderate to severe plaque psoriasis. Made by Johnson & Johnson, it is for adults and teens who are at least 12 years old and weigh over 88 pounds (40 kg).

This is a big deal because it is the first pill of its kind—an oral peptide—that blocks a specific protein called IL-23, which causes skin inflammation. Usually, people have to try many different skin creams before getting a pill. Doctors are calling this a "game-changer" because studies with 2,500 patients showed it works incredibly well, even on tough areas like the scalp. Plus, it has very few side effects, making it a safe and easy choice for clearer skin.

For more details, see rssapp-healio-com-infectious-disease at healio.com/news/dermatology/20260318/fda-approves-icotrokinra-first-oral-peptide-for-adults-and-teens-with-plaque-psoriasis (opens in new tab)